Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity
A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2020.569955/full |
| id |
doaj-d86cd48221ed46f796e24d491ceb7a8c |
|---|---|
| record_format |
Article |
| spelling |
doaj-d86cd48221ed46f796e24d491ceb7a8c2021-02-10T08:28:03ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-02-011110.3389/fphar.2020.569955569955Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without CardiotoxicityZoltán Szabó0Lilla Hornyák1Márton Miskei2Lóránt Székvölgyi3Lóránt Székvölgyi4Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, Debrecen, HungaryMTA-DE Momentum Genome Architecture and Recombination Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Doctoral School of Molecular Cell and Immune Biology, Debrecen, HungaryMTA-DE Momentum Genome Architecture and Recombination Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Doctoral School of Molecular Cell and Immune Biology, Debrecen, HungaryMTA-DE Momentum Genome Architecture and Recombination Research Group, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Doctoral School of Molecular Cell and Immune Biology, Debrecen, HungaryFaculty of Pharmacy, University of Debrecen, Debrecen, HungaryA serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation without causing cardiotoxicity. Future introduction of recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) is expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions.https://www.frontiersin.org/articles/10.3389/fphar.2020.569955/fullMAPK/ERK pathwaybaxcancer therapyclinical trialcardiotoxicity |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Zoltán Szabó Lilla Hornyák Márton Miskei Lóránt Székvölgyi Lóránt Székvölgyi |
| spellingShingle |
Zoltán Szabó Lilla Hornyák Márton Miskei Lóránt Székvölgyi Lóránt Székvölgyi Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity Frontiers in Pharmacology MAPK/ERK pathway bax cancer therapy clinical trial cardiotoxicity |
| author_facet |
Zoltán Szabó Lilla Hornyák Márton Miskei Lóránt Székvölgyi Lóránt Székvölgyi |
| author_sort |
Zoltán Szabó |
| title |
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity |
| title_short |
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity |
| title_full |
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity |
| title_fullStr |
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity |
| title_full_unstemmed |
Two Targets, One Hit: new Anticancer Therapeutics to Prevent Tumorigenesis Without Cardiotoxicity |
| title_sort |
two targets, one hit: new anticancer therapeutics to prevent tumorigenesis without cardiotoxicity |
| publisher |
Frontiers Media S.A. |
| series |
Frontiers in Pharmacology |
| issn |
1663-9812 |
| publishDate |
2021-02-01 |
| description |
A serious adverse effect of cancer therapies is cardiovascular toxicity, which significantly limits the widespread use of antineoplastic agents. The promising new field of cardio-oncology offers the identification of potent anti-cancer therapeutics that effectively inhibit cancer cell proliferation without causing cardiotoxicity. Future introduction of recently identified cardio-safe compounds into clinical practice (including ERK dimerization inhibitors or BAX allosteric inhibitors) is expected to help oncologists avoid unwanted cardiological complications associated with therapeutic interventions. |
| topic |
MAPK/ERK pathway bax cancer therapy clinical trial cardiotoxicity |
| url |
https://www.frontiersin.org/articles/10.3389/fphar.2020.569955/full |
| work_keys_str_mv |
AT zoltanszabo twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity AT lillahornyak twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity AT martonmiskei twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity AT lorantszekvolgyi twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity AT lorantszekvolgyi twotargetsonehitnewanticancertherapeuticstopreventtumorigenesiswithoutcardiotoxicity |
| _version_ |
1724275504338436096 |